Clinical Pharmacokinetics of Digoxin 1980

Clinical Pharmacokinetics

Volumn 5, Issue 2, 1980, Pages 137-149

  Aronson, Jeffrey K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; COLESTYRAMINE; DIGOXIN; DIHYDRODIGOXIN; METOCLOPRAMIDE; QUINIDINE;

ANIMAL EXPERIMENT; DIGOXIN DERIVATIVE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INTERACTION; DRUG PROTEIN BINDING; DRUG TOXICITY; DRUG URINE LEVEL; HEART; HEART FAILURE; HUMAN CELL; INTOXICATION; PHARMACOKINETICS;

ABSORPTION; AGED; BIOTRANSFORMATION; DIGOXIN; DOSAGE FORMS; DRUG INTERACTIONS; FEMALE; HEART; HUMAN; KIDNEY DISEASES; KINETICS; PREGNANCY; PROTEIN BINDING; THYROID DISEASES; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0019165822     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-198005020-00002     Document Type: Article

References (92)

1. Passage of digoxin into cerebrospinal fluid in man
2. The foeto-maternal distribution of digoxin in early human pregnancy
3. The effect on serum enzymes of intramuscular injections of digoxin, bumetanide, pentazocine and isotonic sodium chloride
4. Post-mortem distribution and tissue concentrations of digoxin in infants and adults
5. Cardiac glycosides and drugs used in dysrhythmias
6. Monitoring digoxin therapy: III How useful are the nomograms?
7. Cardiac glycosides and drugs used in dysrhythmias
8. Altered distribution of digoxin in renal failure — a cause of digoxin toxicity?
9. Monitoring digoxin therapy: II
10. Monitoring digoxin therapy: I
11. Monitoring digoxin therapy: The use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity
12. Concentration of digoxin in choroid plexus
13. Relationship of serum and myocardial digoxin concentration to electrocardiographic estimation of digoxin intoxication
14. Plasma and myocardial digoxin concentrations in patients on oral therapy
15. The pharmacokinetics of digoxin in patients with manifest hyperthyroidism and after normalization of thyroid function
16. Binding of digitoxin and digoxin to normal human β-lipoproteins
17. Pharmacology of nutrition
18. Effects of maintenance digoxin therapy on systolic time intervals and serum digoxin concentrations
19. Digoxin concentrations in the serum and myocardium of digitalised patients
20. Plasma and tissue digoxin concentrations in patients undergoing cardiopulmonary bypass
21. Plasma digoxin concentrations in patients with atrial fibrillation
22. Transfer of digoxin across the placenta and into breast milk
23. Dihydrodigoxin: A common metabolite of digoxin in man
24. Alteration in intracellular sodium concentration and ouabain-sensitive ATPase in erythrocytes from hyperthyyroid patients
25. Physiological distribution of digoxin in human heart
26. Myocardial and skeletal muscle concentrations of digoxin in patients on long-term therapy
27. Serum digoxin in patients with thyroid disease
28. Digoxin in the elderly: Pharmacokinetic consequences of old age
29. Digoxin: linearity between dose and serum concentration
30. Quinidine-digoxin interaction
31. Digoxin metabolism in hypo-and hyperthyroidism
32. The distribution and concentration of tritiated digoxin in human tissues
33. Acute digoxin poisonings: review of therapy
34. 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation
35. Cerebrospinal fluid digoxin concentrations in humans
36. Bioavailability of digoxin in a new soluble pharmaceutical formulation in capsules
37. Untersuchungen zur Pharmakokinetik von Digoxin bei hyperthyreoten Patienten
38. Inefficacy of “therapeutic” serum levels of digoxin in controlling the ventricular rate in atrial fibrillation
39. Correlation of serum concentrations with heart concentrations of digoxin in human subjects
40. Digoxin — quinidine interaction
41. Determinants of the renal clearance of digoxin
42. Tritiated digoxin XVI. Gastric absorption
43. Tritiated digoxin XXII. Absorption and excretion in malabsorption syndromes
44. Human serum and myocardium digoxin
45. Absorption of digoxin in patients with malabsorption syndromes
46. Comparative studies of the protein binding of digoxin and its metabolites
47. Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals
48. Effect of quinidine on plasma concentration of digoxin
49. Digoxin in hyperthyroidism
50. Clinical pharmacokinetics of digoxin
51. Myocardial digoxin concentrations in fatal intoxications
52. The serum digitalis concentration — does it diagnose digitalis toxicity?
53. The mechanism of the calorigenic action of thyroid hormone
54. A completely absorbed oral preparation of digoxin
55. Digoxin dosage regimens —A comparison of intuitive and predicted digoxin prescribing
56. Digoxin absorption from tablets and elixir
57. Myocardial distribution of digoxin and renal function
58. Tissue concentrations of digoxin in an autopsy material
59. Dissociation of the inotropic effect of digitalis from its effect on atrioventricular conduction
60. Digoxin concentration in choroid plexus, brain and myocardium in old age
61. Uraemic and normal plasma protein binding of various cardiac glycosides under ‘in vivo’ conditions
62. Digoxin kinetics in patients with thyroid dysfunction
63. Role of the nervous system in the genesis of cardiac rhythm disorders
64. Excretion of drugs in human milk
65. Human myocardium and plasma digoxin concentration in patients on long-term digoxin therapy
66. Quantitation of digoxigenin in serum following oral administration of digoxin in humans
67. Digoxin excretion in human breast milk
68. Unusually large digitalis requirements — study of altered digoxin metabolism
69. Superior bioavailability of digoxin solution in capsules
70. Studies on digitalis
71. Dose-independent pharmacokinetics of digoxin in humans
72. Relationship between plasma concentration and dose of digoxin in patients with and without renal impairment
73. Computer-assisted digoxin therapy
74. Plasma digoxin levels and the interbeat interval signal in atrial fibrillation
75. Digoxin metabolism in patients
76. Effect of digitalis on systolic time intervals in thyrotoxicosis
77. Plasma digoxin concentration — its relation to digoxin dosage and clinical effects in patients with atrial fibrillation
78. The ratio between myocardial and plasma levels of digoxin in man
79. Role of pharmacokinetics in drug dosage adjustment
80. Serum digoxin concentrations in the human fetus, neonate and infant
81. Relationship of plasma digitoxin and digoxin to cardiac response following intravenous digitalisation in man
82. Plasma and urinary digoxin in thyroid dysfunction
83. Effect of digoxin on A-V conduction
84. Renal tubular secretion of digoxin
85. Plasma digoxin after parenteral administration
86. Decreased volume of distribution of digoxin in a patient with renal failure
87. Loading and maintenance doses of digoxin in patients with normal renal function and those with severely impaired renal function
88. Correlation of plasma levels of digoxin in patients with dose and measure of renal function
89. Spironolactone-induced changes in digoxin kinetics
90. Serum and tissue concentrations of digoxin. A clinical and pathologic analysis
91. Is a slow pulse rate a reliable sign of digitalis toxicity?